We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Language in Primary Progressive Aphasia

This study is currently recruiting participants.
Verified September 2017 by Marsel Mesulam, Northwestern University
Sponsor:
ClinicalTrials.gov Identifier:
NCT00537004
First Posted: September 28, 2007
Last Update Posted: September 13, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
National Institute on Deafness and Other Communication Disorders (NIDCD)
Information provided by (Responsible Party):
Marsel Mesulam, Northwestern University
September 26, 2007
September 28, 2007
September 13, 2017
May 2007
April 2022   (Final data collection date for primary outcome measure)
Neuropsychological variables [ Time Frame: Immediately after testing and at two years post-testing ]
Not Provided
Complete list of historical versions of study NCT00537004 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Language in Primary Progressive Aphasia
Language in Primary Progressive Aphasia
The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.

The Language in Primary Progressive Aphasia (PPA) aims to understand the behavioral, anatomical and physiological changes in people with PPA throughout the course of the illness. The researchers in this study want to increase awareness of PPA, educate others about this unique disorder, and to encourage more research to eventually develop therapies.

During the three-day research program, participants will be asked to undergo neuropsychological testing (paper and pencil tests that evaluate cognition), an MRI (a non-invasive brain-imaging procedure), an EEG (another non-invasive procedure that looks at brain waves when you think) and other computer and language testing batteries. Participants may be asked to return every two years to complete the same measures.

The study will recruit approximately 15 participants with PPA per year. For participants not living near Chicago, IL, flights and accommodations (for both the person with PPA and their companion) will be covered by the study.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Participants with PPA will be recruited from the Northwestern University Alzheimer's Disease Center Core registry, the Northwestern University Neurobehavior and Memory Clinic, and from those who contact the center that are interested in PPA research.
Primary Progressive Aphasia
Not Provided
  • PPA (Primary Progressive Aphasia)
    Individuals with primary progressive aphasia
  • Control
    Individuals with no diagnosis of any type of dementia

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
April 2023
April 2022   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of primary progressive aphasia
  • Right-handed
  • English speaker
  • Visual acuity of 20/30 corrected
  • Adequate hearing to follow conversation
  • Safe for an MRI scan

Exclusion Criteria:

  • Left-handedness
  • Claustrophobia
  • Presence of significant medical illness that initially or in the future could interfere with continued participation in the study
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact: Benjamin Rader 312-908-9681 benjamin.rader@northwestern.edu
United States
 
 
NCT00537004
IA0125
R01DC008552 ( U.S. NIH Grant/Contract )
No
Not Provided
Not Provided
Marsel Mesulam, Northwestern University
Northwestern University
National Institute on Deafness and Other Communication Disorders (NIDCD)
Principal Investigator: Marsel Mesulam, MD Northwestern University Feinberg School of Medicine
Northwestern University
September 2017